These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

38 related articles for article (PubMed ID: 8925760)

  • 1. [A rapid rise in the number of type-2 diabetics in kidney failure. Not just a problem of nephrologists].
    Ritz E; Lippert J; Keller C
    Dtsch Med Wochenschr; 1996 Oct; 121(41):1247. PubMed ID: 8925760
    [No Abstract]   [Full Text] [Related]  

  • 2. [A cost analysis of diagnostic screening for the differentiation of type-1 and type-2 diabetics aged 30 to 45. A health economics modelling calculation].
    Kilburg A; Bruchhausen Y; Thomas J; Rychlik R
    Dtsch Med Wochenschr; 1999 Dec; 124(50):1510-7. PubMed ID: 10633777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Juvenile obesity and comorbidity type 2 diabetes mellitus (T2 DM) in Germany: development and cost-of-illness analysis].
    Wolfenstetter SB
    Gesundheitswesen; 2006 Oct; 68(10):600-12. PubMed ID: 17099820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Economic significance of diabetes in Germany].
    Ammon HP
    Med Monatsschr Pharm; 1999 Mar; 22(3):65-6. PubMed ID: 10097579
    [No Abstract]   [Full Text] [Related]  

  • 5. [A cost of illness study of diabetes mellitus].
    von Ferber L; Köster I; Hauner H
    Gesundheitswesen; 1997 Jan; 59(1):17-22. PubMed ID: 9138642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of losartan on the lifetime incidence of ESRD and costs in Mexico.
    Arredondo A; Burke TA; Carides GW; Lemus E; Querol J
    Rev Invest Clin; 2005; 57(3):399-405. PubMed ID: 16187699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Costs of type 2 diabetes in Germany. Results of the CODE-2 study].
    Liebl A; Neiss A; Spannheimer A; Reitberger U; Wagner T; Görtz A
    Dtsch Med Wochenschr; 2001 May; 126(20):585-9. PubMed ID: 11402924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Medical resources consumption of type 2 diabetics in France in 1998].
    Detournay B; Fagnani F; Pribil C; Eschwège E
    Diabetes Metab; 2000 May; 26(3):225-31. PubMed ID: 10880898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [By the year 2030 some 40% of the German population could be Type 2 diabetics--the big bang in the public health system].
    Fuessl HS
    MMW Fortschr Med; 2006 May; 148(21):27. PubMed ID: 16796184
    [No Abstract]   [Full Text] [Related]  

  • 10. [Kidney failure in an elderly woman].
    Metsärinne K; Pettersson T; Törnroth T; Tikkanen I
    Duodecim; 2000; 116(9):973-81. PubMed ID: 11988999
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical and economic impact of diabetes following coronary artery bypass.
    Stewart RD; Lahey SJ; Levitsky S; Sánchez C; Campos CT
    J Surg Res; 1998 May; 76(2):124-30. PubMed ID: 9698511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The costs of diabetes mellitus and its complications in Germany].
    Hauner H
    Dtsch Med Wochenschr; 2006 Dec; 131 Suppl 8():S240-2. PubMed ID: 17139578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results.
    Remuzzi G; Ruggenenti P; Perna A; Dimitrov BD; de Zeeuw D; Hille DA; Shahinfar S; Carides GW; Brenner BM;
    J Am Soc Nephrol; 2004 Dec; 15(12):3117-25. PubMed ID: 15579515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Diabetes mellitus and heart failure - incidence and surgical therapy options].
    Reiss N; Kleikamp G; Tenderich G; Tschöpe D; Körfer R
    Herz; 2008 Apr; 33(3):206-10. PubMed ID: 18568315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Costs of long-term complications in type 2 diabetes patients in Germany. Results of the CODE-2 Study].
    Liebl A; Spannheimer A; Reitberger U; Görtz A
    Med Klin (Munich); 2002 Dec; 97(12):713-9. PubMed ID: 12491064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [How to defuse the diabetes mellitus time bomb: identify early signs and vascular injuries, minimize risk factors].
    Janka HU
    MMW Fortschr Med; 2003 May; 145(21):29-30. PubMed ID: 12845863
    [No Abstract]   [Full Text] [Related]  

  • 17. Epidemiology of complications and total treatment costs from diagnosis of Type 2 diabetes in Germany (ROSSO 4).
    Martin S; Schramm W; Schneider B; Neeser K; Weber C; Lodwig V; Heinemann L; Scherbaum WA; Kolb H
    Exp Clin Endocrinol Diabetes; 2007 Sep; 115(8):495-501. PubMed ID: 17853332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidemiology and costs of diabetes treated with insulin in France.
    Detournay B; Raccah D; Cadilhac M; Eschwège E
    Diabetes Metab; 2005 Jun; 31(3 Pt 2):3-18. PubMed ID: 16142041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Patient classification and analysis of risk profiles for type 2 diabetics as the main focus point in practice. Results of the TEMPO study].
    Lippmann-Grob B; Bierwirth RA; Kron P; Leinhos B; Funke K; Huptas M; Grüneberg M; Weich KW; Münscher C; Potthoff F
    Dtsch Med Wochenschr; 2004 Jan; 129(3):75-81. PubMed ID: 14724780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and cost-effectiveness of primary prevention of Type 2 diabetes in a 'real world' routine healthcare setting: model based on the KORA Survey 2000.
    Icks A; Rathmann W; Haastert B; Gandjour A; Holle R; John J; Giani G;
    Diabet Med; 2007 May; 24(5):473-80. PubMed ID: 17381502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 2.